Medroxyprogesterone acetate increases anthracyclines uptake in chronic lymphatic leukemia cells: Role of nitric oxide and lipid peroxidation

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 33-42

  Pagnini, U ^a   Pacilio, C ^b   Florio, S ^a   Crispino, A ^a   Claudio, P P ^a,b   Giordano, A ^b   Pagnini, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anthracyclines; Lipid peroxidation; MPA; Nitric oxide

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; IDARUBICIN; MEDROXYPROGESTERONE ACETATE; NITRIC OXIDE;

ARTICLE; CARDIOTOXICITY; CHEMICAL MODIFICATION; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKOCYTE; LIPID PEROXIDATION; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; BIOLOGICAL TRANSPORT; CELL NUCLEUS; CHEMISTRY, PHYSICAL; DOXORUBICIN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; IDARUBICIN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKOCYTES; LIPID PEROXIDATION; MALONDIALDEHYDE; MEDROXYPROGESTERONE 17-ACETATE; MEMBRANE LIPIDS; NEOPLASM PROTEINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; NITROPRUSSIDE; TUMOR STEM CELLS; VITAMIN E;

EID: 0034027686     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Booser DJ and Hortobagyi GN: Anthracycline antibiotics in cancer therapy. Focus on drug resistance Drugs 47: 223-258, 1994.
2. Saltiel E., and Mc.Guire W: Doxorubicin (adriamycin) cardiomyopathy Western J Med 139: 332-341, 1983.
3. Young RCN, Ozols RF and Myers CE: The anthracycline antineoplastic drugs Engl J Med 305: 139-153, 1981.
4. Kantrowitz NE, Bristow MR: Cardiotoxicity of antitumour agents. Progr Cardiovascular Dis 27: 195-200, 1984.
5. Marie JP, Zittoun R, Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586-92, 1991.
6. Baines P, Limaye M, Hoy T, Padua RA, Whittaker J, al-Sabath A, Burnett A: In vitro drug resistance in acute myeloid and chronic B-lymphocytic Leukaemic blasts and in normal blood and marrow populations. Leukemia Res 18: 683-91, 1994.
7. Bennis S, Ichas F, Robert J: Differential effects of verapamil and quinine on the reversal of doxorubicin resistance in a human leukemia cell line. Int J Cancer 62: 283-90, 1995.
8. Yusa K and Tsuruo T: Reversal mechanism of multidrug-resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 49: 5003-5006, 1989.
9. Sonnevel P, Durie BG, Lokhurst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg G and Noore K: Modulation of multi-drug resistant multiple myeloma by ciclosporin. Lancet 340: 255-259, 1992.
10. Merlin JL, Guerci A, Marchal S, Massoum N, Ramacci C, Humbert JC, Tsuruo T and Guerci O: Comparative evaluation of S9788, verapamil and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein expressing samples from patients with hematologic malignancies. Blood 84: 262-269, 1994.
11. Reichle A, Diddens H, Altmayr F, Rastetter J, Abdreesen R: Chemomodulation of drug involved in multidrug resistance in chronic lymphatic leukemia of the B-cell type. Cancer Chem Pharm34: 307-316, 1994.
12. Haberl I, Swatonek H, Schaufler K, Uleperger E, Wenzl E, Theyer G, Hamilton G, Thalhammer T: P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. Int J Oncol 12: 1137-1142 (1998.
13. Ozols RF, Cunnion RE, Klecker RW, Hamilton TC, Ostchega Y, Parillo JE and Young RC: Verapamil and adryamicin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5: 5002-5006, 1987.
14. Dalton WS: Drug resistance: modulation in the laboratory and clinic. Seminars Oncol 20: 64-69, 1993.
15. Sikie BI: Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635, 1993.
16. Kave SB: P-glycoprotein (P-gp) and drug resistance-time for reappraisals Brit J Cancer 67: 703-707, 1993.
17. Wang L, Yang CPH, Horwitz SB, Trail PA and Casazza AM: Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. Cancer Chem Pharm 34: 96-102, 1994.
18. Fleming GF, Amato JM, Agresti M and Safa AR: Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chem Pharm29: 445-449, 1992.
19. Cavalli F, Goldhirsch A, Jungi F, Marta G, Mermillod B and Alberto F: Randomized trial of low - versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clinical Oncol 2 (5): 414-419, 1984.
20. Hupperets PS, Wils J, Volovics L, Schuten L, Fickers M, Bron H, Schouten HC, Jager J, Smeets J and De Jong J: Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracile (CAF) with or without medroxyprogesterone acetate for node positive breast cancer patients. Annals Oncol 4: 295-301, 1993.
21. Anderstrom C: Experiences with doxo/epirubicin and medroxyprogesterone acetate (MPA) in prostatic cancer. Cancer Chem Pharm35, Supplement S97-S100, 1994.
22. Turner MJ 3d. Everman DB, Ellington SP, Fields CE: Detenction of free radicals during the cellular metabolism of adryamicin. Free Radicals Biol Med 9(5): 415-421, 1990.
23. Goodman J, and Hochstein P: Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Comm 77: 797-803, 1977.
24. Svingen BA and Powis G: Pulse radiolysis studies of antitumor quinones: radical lifetimes, reactivity with oxygen. and one-electron reduction potentials. Archives of Biochem Biophys 209: 119-126, 1981.
25. Luo D and Vincent SR: Inhibition of nitric oxide synthase by antineoplastic anthracyclines. Biochem Pharm 47: 2111-2112, 1944.
26. Nicolay K, Timmers RJM, Spoelstra E, Van der Neut R, Fok JJ, Huigen Y, Verkleij A and De Kruijff B: The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes. Biochim Biophys Acta 778: 359-371, 1994.
27. Escriba PV, Ferrier-Montiel AV, Ferragaut JA and Gonzalez-ros JM: Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochem 1990 29: 7275-82, 1990.
28. De Wolf FA, Demel RA, Bets D, Van Kats C and De Kruijff B: Characterization of the interaction of doxorubicin with (poly)phosphoinositides in model systems. Evidence for specific interaction with phosphatidylinositol monophosphate and -diphosphate. Febs Letters 288: 237-240, 1991.
29. De Wolf FA, Maliepaard M, Van Dorsten F, Berghuis I, Nicolay K and De Kruijff B: Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics.Biochim Biophys Acta 1096: 67-80, 1991.
30. De Wolf FA, Staffhorst RWHM, Smits HP, Onwezen MF and De Kruijff B: Role of anionic phospholipids in the interaction of doxorubicin and plasma membrane vesicles: drug binding and structural consequences in bacterial systems. Biochem 32: 6688-6695, 1993.
31. Halliwell B and Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease: an overview.Methods Enzymol 186: 1-85, 1990.
32. Toyokuni, S, Okamoto K, Yodoi J and Hiai H: Persistent oxidative stress in cancer. Febs Letters 358: 1-3, 1995.
33. Van Bommel T, Marse T, and Bojar H: Effect of High-Dose Medroxyprogesterone acetate and Various other steroid hormones on plasma membrane lipid mobility in CAMA-1 mammary cancer cells. Anticancer Res 7: 1217-1224, 1987.
34. Speelmans G, Staffhordt RWHM, De Wolf FA, De Kruijff B: Verapamil competes with doxorubicin for binding to anionic phospholipids resulting in increased internal concentrations and rates of passive transport of doxorubicin. Biochim Biophys Acta 1238: 137-146, 1995.
35. Florio S, Pagnini D, Crispino A, Avallone L, Lombardi P, Zuccaro S, Lanni C, Pelagalli A: Preliminary observation on the interference of antiblastic agents in membrane fluidity and leukocyte potential. J Chemotherapy 8: 399-402, 1996.
36. Pacilio C, Florio S, Pagnini U, Crispino A, Claudio PP, Pacilio G, Pagnini G: Modification of membrane fluidity and depolarization by some anthracyclines on different cell lines. Interference by Medroxyprogesterone acetate and Verapamil. Anticancer Res 18: 4027-4034, 1998.
37. Bass DA, Dechatelet LR, McCall CE: Independent stimulation of motilily and the oxidative metabolic burst of human polymorphonuclear leukocytes. J Immunol 121: 172-8, 1978.
38. Esterbauer H and Cheeseman KH: Determination of Aldehydic Lipid Peroxidation Products: Malonaldehyde and 4-Hydroxynonenal. Methods Enzymol 186: 407-421, 1990.
39. Lowry OH, Rosembrough NJ, Farr AL and Randall RJ: Protein mesurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
40. Chandler LJ, Kopnisky K, Richrds E, Crew FT, Sumners C: Angiotensin II decreases inducible nitric oxide synthase in rat astroglial cultures Amer J Physiol 268: C700-C707, 1995.
41. Tarasiuk J, Frezard F, Garnier-Suillerot A: Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta 1013: 109-117, 1989.
42. Praet M, Stryckmans P, Ruysschaert JM: Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells. Biochem Pharmacol 51: 1341-8, 1996.
43. Lesko SA, Lorentzen RJ, Ts'o PO: Role of superoxide in deoxyribonucleic acid strand scission. Biochem 19: 3023-8, 1980.
44. Aruoma OI, Halliwell B, Gajewski E, Dizdaroglu M: Damage to the bases in DNA induced by hydrogen peroxide and ferric ion chelates. J Biol Chem264: 20509-12, 1989.
45. Blakely WF, Fuciarelli AF, Wegher BJ, Dizdaroglu M: Hydrogen peroxide induced base damage in deoxyribonucleic acid. Radiation Res 121: 338-43, 1990.
46. Jourd'heuil D, Kang D, Grisham MB: Intreactions between superoxide and nitric oxide: Implications in DNA damage and mutagenesis. Frontires in Bioscience 2: d189-96, 1997.
47. Olinski R, Zastawny T, Budzbon J, Skokowski J, Zegarski W, Dizdaroglu M: DNA base modifications in chromatin of human cancerous tissues. FEBS Letters 309: 193-8, 1992.
48. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, Olinski R: Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Letters 341: 59-64, 1994.
49. Okamoto K, Toyokuni S, Uchida K, Ogawa O, Takenewa J, Kakehi Y, Kinoshita H, Hattori-Nakakuki Y, Hiai H, Yoshida O: Formation of 8-hydroxy-2′ deoxyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal cell carcinoma. Int J Cancer 58: 825-9, 1994.
50. Senturker S, Karahalil B, Inal M, Yilmaz H, Muslumanoglu H, Gedikoglu G, Dizdaroglu M: Oxidative DNA base damage and antioxidant enzyme levels in childhood acute lymphoblastic leukemia. FEBS Letters 416: 286-90, 1997.
51. Maeda H, Akaike T: Nitric oxide and oxygen radicals in infection, inflammation and cancer. Biochemistry (Moscow) 63: 854-65, 1998.
52. Ohshima H, Bartsch H: Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutation Res 305: 253-64, 1994.
53. Wink DA, Mitchell JB: Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radicals Biol Med 25: 434-56, 1998.
54. Lind DS, Kontaridis MI, Edwards PD, Josephs MD, Moldawer LL, Copeland EM: 3rd. Nitric Oxide contributes to adriamycin's antitumor effect. J Surg Res 69: 283-7, 1997.
55. Vasquez-Viver J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalayanaraman B: Endothelial nitric oxide synthase-dependent speroxide generation from adryamicin. Biochemistry 36: 11293-7, 1997.
56. Mayer LD, Bally MB, Cullis PR: Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857: 123-6, 1986.
57. Chaires JB, Dattagupta N, Crothers DM: Kinetics of the daunomycin-DNA interaction. Biochemistry 24: 260-7, 1985.
58. Capranico G, Zunino F, Kohn KW, Pommier Y: Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 29: 562-9, 1990.
59. Nicolay K, Timmers RJM, Spoelstra E, Van der Neut R, Fok JJ, Huigen Y, Verkleij A and De Kruijff B: The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes. Biochim Biophys Acta 778: 359-371, 1994.
60. Speelmans G, Staffhorst R.W, de Kruijff B. de Wolf F.A. Transport studies of doxorubicin in model membranes indicate a difference in passive diffusion across and binding at the outer and inner leaflets of the plasma membrane. Biochemistry 33: 13761-8, 1994.
61. Duval D, Durant S, Homo Delarche F. Non genomic effects of steroids. Interaction of steroid molecules with membrane structures and functions. Biochimica et Biophysica Acta. 737: 409-42, 1983.